← All trials
NCT05290545
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2024
- First posted
- Mar 22, 2022
- Last posted
- Mar 22, 2022
- Enrollment
- 314
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Southern Medical UniversityLead sponsor
- Guangzhou Medical UniversityCollaborator
- First People's Hospital of ChenzhouCollaborator
- Southern Medical UniversityOverall official - principal investigator
- Southern Medical UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- University of Science and Technology of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.